Application of circulating DNA in colorectal cancer

Abstract

Abstract: Circulating DNA is defined as a kind of extracellular DNA that exists in plasma，cerebrospinal fluid and synovial fluid. The concentration of circulating DNA of cancer patients is significantly higher than that in healthy people. The genetic and epigenetic alterations of circulating cellfree nucleic acids are relevant to cancer development and progression, for example, gene mutation, DNA methylation and microsatellite instability and so on. The quantitative and qualitative detection of circulating DNA shows promising potential value in cancer screening, diagnosis, disease monitoring treatment and prognosis.

Key words: Colorectal neoplasms, Circulating DNA

HUANG Zong-Hua, XU Dan-Dan, ZHANG Fei-Yan, SONG Li-Hua, SONG Xian-Rang. Application of circulating DNA in colorectal cancer[J]. Journal of International Oncology, 2016, 43(2): 152-.

References

［1］ Jemal A, Bray F, Center MM, et al. Global cancer statistics［J］. CA Cancer J Clin, 2011, 61(2): 6990. DOI:10.3322/caac.20107. ［2］ Schwarzenbach H, Hoon DS, Pantel K. Cellfree nucleic acids as biomarkers in cancer patients［J］. Nat Rev Cancer, 2011, 11(6): 426437. DOI:10.1038/nrc3066. ［3］ Mouliere F, Thierry AR. The importance of examining the proportion of circulating DNA originating from tumor, microenvironment and normal cells in colorectal cancer patients［J］. Expert Opin Biol Ther, 2012, 12Suppl 1: S209S215. DOI:10.1517/14712598.2012.688023. ［4］ Bernatsky S, RamseyGoldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment［J］. Ann Rheum Dis, 2014, 73(1): 138142. DOI:10.1136/annrheumdis2012202099. ［5］ Kaiser J. Medicine. Keeping tabs on tumor DNA［J］.Science, 2010, 32(5969): 1074. DOI: 10.1126/science.327.5969.1074. ［6］ Itzkowitz S, Brand R, Jandorf L, et al. A simplified, noninvasive stool DNA test for colorectal cancer detection［J］. Am J Gastroenterol, 2008, 103(11): 28622870. DOI:10.1111/j.15720241.2008.02088.x. ［7］ Kanthan R, Senger JL, Kanthan SC. Fecal molecular markers for colorectal cancer screening［J］. Gastroenterol Res Pract, 2012 (2011): 184343. DOI:10.1155/2012/184343. ［8］ Hao TB, Shi W, Shen XJ, et al. Circulating cellfree DNA in serum as a biomarker for diagnosis and prognostic prediction of colorectal cancer［J］. Br J Cancer, 2014, 111(8): 14821489. DOI:10.1038/bjc.2014.470. ［9］ Danese E, Montagnana M, Minicozzi AM, et al. Realtime polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers［J］. Clin Chem Lab Med, 2010, 48(11): 16651668. DOI:10.1515/CCLM.2010.301. ［10］ Flamini E, Mercatali L, Nanni O, et al. Free DNA and carcinoembryonic antigen serum levels: an important combination for diagnosis of colorectal cancer［J］. Clin Cancer Res, 2006, 12(23): 69856988. DOI:10.1158/10780432.CCR061931. ［11］ Holdenrieder S, Dharuman Y, Standop J, et al. Novel serum nucleosomics biomarkers for the detection of colorectal cancer［J］. Anticancer Res, 2014, 34(5): 23572362. ［12］闫巍, 徐智. 结直肠癌TNM分期与循环DNA水平关系的临床研究［J］. 中国微创外科杂志, 2012, 12(6): 512514. ［13］ Mouliere F, El Messaoudi S, Pang D, et al. Multimarker analysis of circulating cellfree DNA toward personalized medicine for colorectal cancer［J］. Mol Oncol, 2014, 8(5): 927941. DOI:10.1016/j.molonc.2014.02.005. ［14］ Thierry AR, Mouliere F, El Messaoudi S, et al. Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA［J］. Nat Med, 2014, 20(4): 430435. DOI:10.1038/nm.3511. ［15］ Spindler KL, Pallisgaard N, Vogelius I, et al. Quantitative cellfree DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan［J］. Clin Cancer Res, 2012, 18(4): 11771185. DOI:10.1158/10780432.CCR110564. ［16］ Kuo YB, Chen JS, Fan CW, et al. Comparison of KRAS mutation analysis of primary tumors and matched circulating cellfree DNA in plasmas of patients with colorectal cancer［J］. Clin Chim Acta, 2014, 433(433): 284289. DOI:10.1016/j.cca.2014.03.024. ［17］闫巍, 张能维, 徐智, 等. 结直肠癌患者手术前后循环DNA水平的变化及其意义［J］. 中国普通外科杂志, 2013, 22(12): 16271630. DOI:10.7659/j.issn.10056947.2013.12.021. ［18］ Agostini M, Pucciarelli S, Enzo MV, et al. Circulating cellfree DNA: a promising marker of pathologic tumor response in rectal cancer patients receiving preoperative chemoradiotherapy［J］. Ann Surg Oncol, 2011, 18(9): 24612468. DOI:10.1245/s104340111638y. ［19］ Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early and latestage human malignancies［J］. Sci Transl Med, 2014, 6(224): 224ra24. DOI:10.1126/scitranslmed.3007094. ［20］ Lefebure B, Charbonnier F, Di Fiore F, et al. Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer［J］. Ann Surg, 2010, 251(2): 275280. DOI:10.1097/SLA.0b013e3181c35c87.

[1]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[2]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[3]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.
[4]	Sun Guobao, Yang Qian, Zhuang Qingchun, Gao Binbin, Sun Xiaogang, Song Wei, Sha Dan. Research progress on the histopathological growth patterns of colorectal liver metastasis [J]. Journal of International Oncology, 2024, 51(2): 114-118.
[5]	Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong. Expression and clinical significance of ASB6 in colorectal cancer tissues [J]. Journal of International Oncology, 2023, 50(8): 470-474.
[6]	Chen Zhuo, Tao Jun, Chen Lin, Ke Jing. Value of detection of peripheral blood miR-194 combined with fecal miR-143 in the clinical screening of colorectal cancer [J]. Journal of International Oncology, 2023, 50(5): 268-273.
[7]	Huang Zhen, Zhang Caiyutian, Ke Shaobo, Shi Wei, Zhao Wensi, Chen Yongshun. Construction of postoperative prognosis model for patients with colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 157-163.
[8]	Xu Liangfu, Li Yuanfei. Research progress on tumor microenvironment and immune combination therapy of MSS colorectal cancer [J]. Journal of International Oncology, 2023, 50(3): 186-190.
[9]	Liu Yujie, Zhao Zhiqiang, Wang Zicheng. Levels and diagnostic value of TOP2A and ERBB2 in peripheral blood mononuclear cells of patients with early colorectal cancer [J]. Journal of International Oncology, 2023, 50(12): 717-722.
[10]	Tao Hong, Yin Hong, Luo Hong, Tao Jiayu. Potential strategies for targeting tumor-associated macrophages to enhance the efficacy of immune checkpoint inhibitors for colorectal cancer [J]. Journal of International Oncology, 2023, 50(11): 683-687.
[11]	Wang Xi, Wu Chuanqing. Research progress in reversing multidrug resistance in colorectal cancer [J]. Journal of International Oncology, 2023, 50(1): 42-46.
[12]	Gao Yizhao, Liu Yang, Liu Qiulong, Xing Jinliang. Application of circulating cell-free nucleic acid in clinical diagnosis and treatment of colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 555-559.
[13]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[14]	Zhao Ying, Zhang Gehong. Study on the correlations between AGR, PLR and NLR changes and chemotherapy efficacy of metastatic colorectal cancer [J]. Journal of International Oncology, 2022, 49(8): 473-477.
[15]	Huang Mengpan, Wang Xuehong, Lu Yongfu. Mechanism of FOXA2 in colorectal cancer and its application in diagnosis and treatment [J]. Journal of International Oncology, 2022, 49(8): 490-493.